» Articles » PMID: 19699092

Deubiquitinase Activities Required for Hepatocyte Growth Factor-induced Scattering of Epithelial Cells

Overview
Journal Curr Biol
Publisher Cell Press
Specialty Biology
Date 2009 Aug 25
PMID 19699092
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

The scattering response of epithelial cells to activation of the Met receptor tyrosine kinase represents one facet of an "invasive growth" program. It is a complex event that incorporates loss of cell-cell adhesion, morphological changes, and cell motility. Ubiquitination is a reversible posttranslational modification that may target proteins for degradation or coordinate signal transduction pathways. There are approximately 79 active deubiquitinating enzymes (DUBs) predicted in the human genome. Here, via a small interfering RNA (siRNA) library approach, we have identified 12 DUBs that are necessary for aspects of the hepatocyte growth factor (HGF)-dependent scattering response of A549 cells. Different phenotypes are evident that range from full loss of scattering, similar to receptor knockdown (e.g., USP30, USP33, USP47), to loss of cell-cell contacts even in the absence of HGF but defective motility (e.g., USP3, ATXN3L). The knockdowns do not incur defective receptor, phosphatidylinositol 3-kinase, or MAP kinase activation. Our data suggest widespread involvement of the ubiquitin system at multiple stages of the Met activation response, implying significant crosstalk with phosphorylation-based transduction pathways. Development of small-molecule inhibitors of particular DUBs may offer a therapeutic approach to contain metastasis.

Citing Articles

USP50 suppresses alternative RecQ helicase use and deleterious DNA2 activity during replication.

Mackay H, Stone H, Ronson G, Ellis K, Lanz A, Aghabi Y Nat Commun. 2024; 15(1):8102.

PMID: 39284827 PMC: 11405836. DOI: 10.1038/s41467-024-52250-4.


The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases.

Potapenko A, Davidson J, Lee A, Laird A Biochem J. 2024; 481(6):461-480.

PMID: 38497605 PMC: 11088879. DOI: 10.1042/BCJ20240017.


Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.

Yuan T, Zeng C, Liu J, Zhao C, Ge F, Li Y Signal Transduct Target Ther. 2024; 9(1):11.

PMID: 38177135 PMC: 10766984. DOI: 10.1038/s41392-023-01706-y.


Deubiquitylating Enzymes in Cancer and Immunity.

Ren J, Yu P, Liu S, Li R, Niu X, Chen Y Adv Sci (Weinh). 2023; 10(36):e2303807.

PMID: 37888853 PMC: 10754134. DOI: 10.1002/advs.202303807.


Functional implications of paralog genes in polyglutamine spinocerebellar ataxias.

Felicio D, du Merac T, Amorim A, Martins S Hum Genet. 2023; 142(12):1651-1676.

PMID: 37845370 PMC: 10676324. DOI: 10.1007/s00439-023-02607-4.


References
1.
Lai J, Kao S, Jiang S, Tang M, Chan P, Chen H . Involvement of focal adhesion kinase in hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells. J Biol Chem. 2000; 275(11):7474-80. DOI: 10.1074/jbc.275.11.7474. View

2.
Jeffers M, Taylor G, Weidner K, Omura S, Woude G . Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol Cell Biol. 1997; 17(2):799-808. PMC: 231806. DOI: 10.1128/MCB.17.2.799. View

3.
Li Z, Na X, Wang D, Schoen S, Messing E, Wu G . Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2001; 277(7):4656-62. DOI: 10.1074/jbc.M108269200. View

4.
Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S . Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res. 2007; 13(1):27-37. DOI: 10.1158/1078-0432.CCR-06-0824. View

5.
Masuda-Robens J, Kutney S, Qi H, Chou M . The TRE17 oncogene encodes a component of a novel effector pathway for Rho GTPases Cdc42 and Rac1 and stimulates actin remodeling. Mol Cell Biol. 2003; 23(6):2151-61. PMC: 149457. DOI: 10.1128/MCB.23.6.2151-2161.2003. View